Broadcast Date: November 15, 2018
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
When assessing a potential biological therapeutic candidate, several histopathological technologies are typically employed. This ensures the target expression is validated in both normal and diseased tissues before proceeding with pre-clinical studies. Protein B is a transmembrane glycoprotein that is overexpressed in numerous cancers, including triple-negative breast cancer and is often correlated with the metastatic phenotype. In this GEN webinar, we will discuss the process involved in a typical molecular pathology laboratory. Control cell lines and the RNAScope® Assay were utilized to validate the immunohistochemistry protocol. Next, the protein B expression was confirmed in the normal human tissues, then the corresponding gene for Protein B, (Gene B mRNA) was assessed and subsequently validated using RNAscope® RNA in situ hybridization technology. Studies determined high protein B expression level in the skin and mammary glands with very minimal expression in other tissues. Further studies included confocal microscopy in determining if protein B is a good candidate for therapeutic intervention.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Kumar Shanmukhappa, D.V.M., Ph.D.
Senior Investigator, Pre-Clinical Safety
Novartis Institute of Biomedical Research
Courtney Anderson, Ph.D
Applications Leader, Senior Scientist
Advanced Cell Diagnostics